Managing rheumatic and musculoskeletal diseases-past, present and future

Nature Reviews Rheumatology

Volumn 13, Issue 7, 2017, Pages 443-448

  Burmester, Gerd R ^a   Bijlsma, Johannes W J ^b   Cutolo, Maurizio ^c   McInnes, Iain B ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIPERINUCLEAR FACTOR; BARICITINIB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; KERATIN ANTIBODY; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ANKYLOSING SPONDYLITIS; CAPILLAROSCOPY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HIP ARTHROPLASTY; HIP OSTEOARTHRITIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KNEE OSTEOARTHRITIS; LABORATORY DIAGNOSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MINIMALLY INVASIVE SURGERY; MUSCULOSKELETAL DISEASE; NAILFOLD CAPILLAROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PATIENT PARTICIPATION; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SELF CARE; SPONDYLARTHRITIS; TOTAL KNEE ARTHROPLASTY; DISEASE MANAGEMENT; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; QUALITY OF LIFE;

ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DISEASE MANAGEMENT; HUMANS; MUSCULOSKELETAL DISEASES; OCCUPATIONAL THERAPY; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; RHEUMATIC DISEASES;

EID: 85020979060     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2017.95     Document Type: Review

References (50)

1. Bijlsma, J. W. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, doubledummy, strategy trial. Lancet 388, 343-355 (2016).
2. Strehl, C. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from a EULAR task force. Ann. Rheum. Dis. 75, 952-957 (2016).
3. Svartz, N. Salazopyrin, a new sulphanilamide preparation. Acta Med. Scand. 110, 577-598 (1942).
4. Weinblatt, M. E. et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312, 818-822 (1985).
5. Bakker, M. F. et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 156, 329-339 (2012).
6. Smolen, J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76, 960-977 (2017).
7. Johnsen, A. K. & Weinblatt, M. E. in Rheumatology (eds Hochberg, M. C. et al.) 509-517 (Elsevier, 2011).
8. Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-269 (2004).
9. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939 (1999).
10. Siebert, S. et al. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol. Rev. 67, 280-309 (2015).
11. Evaluate Ltd. EvaluatePharma® world preview 2015, outlook to 2020. Evaluate Group http://info. evaluategroup.com/rs/607-YGS-364/images/wp15.pdf (2015).
12. Yamaoka, K. Janus kinase inhibitors for rheumatoid arthritis. Curr. Opin. Chem. Biol. 32, 29-33 (2016).
13. European Medicines Agency. EMA/ CHMP/32752/2017 Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation) Xeljanz (tofacitinib). EMA http:// www.ema.europa.eu/docs/en-GB/document-library/ Summary-of-opinion-Initial-authorisation/ human/004214/WC500220221.pdf (2017).
14. European Medicines Agency. EMA/ CHMP/843822/2016 Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation) Olumiant (baricitinib). EMA http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion-Initial-authorisation/ human/004085/WC500218183.pdf (2016).
15. Daigle, M. E. et al. The cost-effectiveness of total joint arthroplasty: a systematic review of published literature. Best Pract. Res. Clin. Rheumatol. 26, 649-658 (2012).
16. Leon, L. et al. Orthopedic surgery in rheumatoid arthritis in the era of biologic therapy. J. Rheumatol. 40, 1850-1855 (2013).
17. Van der Woude, J. A. et al. Knee joint distraction compared to total knee arthroplasty for treatment of end stage osteoarthritis: simulating long-term outcomes and cost-effectiveness. PLoS ONE. 11, e0155524 (2016).
18. Ruiz, M., Cosenza, S., Maumus, M., Jorgensen, C. & Noël, D. Therapeutic application of mesenchymal stem cells in osteoarthritis. Expert Opin. Biol. Ther. 16, 33-42 (2016).
19. American College of Rheumatology. ARHP distinguished lecturer hails 50 years of advances. ACR Daily News Live http://www.acrdailynewslive.org/arhpdistinguished-lecturer-hails-50-years-of-advances/ (2015).
20. Voshaar, M. J., Nota, I., van de Laar, M. A. & van den Bemt, B. J. Patient-centred care in established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 29, 643-663 (2015).
21. Dörner, T., Egerer, K., Feist, E. & Burmester, G. R. Rheumatoid factor revisited. Curr. Opin. Rheumatol. 16, 246-253 (2004).
22. Puszczewicz, M. & Iwaszkiewicz, C. Role of anticitrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis. Arch. Med. Sci. 7, 189-194 (2011).
23. Aletaha, D. et al. Rheumatoid arthritis classification criteria. An American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580-1588 (2010).
24. Shi, J. et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun. Rev. 13, 225-230 (2014).
25. Ospelt, C. et al. Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-210059 (2017).
26. Hargraves, M. M., Richmond, H. & Morton, R. J. Presentation of two bone marrow elements: the 'tart' cell and the 'L.E.' cell. Proc. Staff Meet. Mayo Clin. 23, 25-28 (1948).
27. Miescher, P. & Fouconnet, M. L'absorption du facteur 'LE' par des noyaux cellulaires isolés [French]. Experimentia 10, 252-254 (1945).
28. Hiepe, F., Dörner, T. & Burmester, G. R. Editorial overview: antinuclear antibody-and extractable nuclear antigen-related diseases. Int. Arch. Allergy Immunol. 123, 5-9 (2000).
29. van der Woude, F. J. et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 8426, 425-429 (1985).
30. Sheehan, N. J. The ramifications of HLA-B27. J. R. Soc. Med. 97, 10-14 (2004).
31. Haase, A., Landwehr, G. & Umbach, E. (eds) Röntgen Centennial: X-rays in Natural and Life Sciences (World Scientific, 1997).
32. Larsen, A., Dale, K. & Eek, M. Radiographic evaluation of rheumatoid arthritis. Acta Radiol. Diagn. (Stockh.) 18, 481-491 (1977).
33. Sharp, J. T. et al. Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum. 27, 61-64 (1985).
34. Van der Heijde, D. M., van Riel, P. L., Nuver-Zuwart, H. H., Gribnau, F. W. & van de Putte, L. B. Effects of hydroxochloroquin and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1846, 1036-1038 (1989).
35. Greenberg, J. O. Obituary: William H. Oldendorf-a tribute. J. Neuroimaging 3, 148-149 (1993).
36. Mishra, S. K. & Singh, P. History of neuroimaging: the legacy of William Oldendorf. J. Child Neurol. 25, 508-517 (2010).
37. Rubin, G. D. Computed tomography: revolutionizing the practice of medicine for 40 years. Radiology 273, S45-S74 (2014).
38. Two Views. A quick history of the MRI in two views-words and pictures. Two Views http://www.two-views. com/mri-imaging/history.html#sthash. GbJKG4v0.7vGwlRGx.dpbs (2016).
39. Lassere, M. et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Exercise 3: an international multicenter reliability study using the RA-MRI Score. J. Rheumatol. 30, 1366-1375 (2003).
40. Woo, J. A short history of the development of ultrasound in obstetrics and gynecology. Ob-ultrasound http://www.ob-ultrasound.net/history1. html (2002).
41. Gompelt, B. M. & Darlington, L. G. Grey scale ultrasonography and evaluation of popliteal cyst. Clin. Radiol. 30, 539-545 (1979).
42. Graf, R. The diagnosis of congenital hip-joint dislocation by the ultrasonic Combound treatment. Arch. Orthop. Trauma Surg. 97, 117-133 (1980).
43. Backhaus, M. et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann. Rheum. Dis. 60, 641-649 (2001).
44. Maricq, H. R. & LeRoy, E. C. Patterns of finger capillary abnormalities in connective tissue disease by 'widefield' microscopy. Arthritis Rheum. 16, 619-628 (1973).
45. Cutolo, M., Sulli, A. & Smith, V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat. Rev. Rheumatol. 6, 578-587 (2010).
46. Abdollahi-Roodsaz, S., Abramson, S. B. & Scher, J. U. The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nat. Rev. Rheumatol. 12, 446-455 (2016).
47. van der Vlist, M., Kuball, J., Radstake, T. R. & Meyaard, L. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat. Rev. Rheumatol. 12, 593-604 (2016).
48. Topol, E. Digital medicine: empowering both patients and clinicians. Lancet 388, 740-741 (2016).
49. Barnes, C. G. The History of EULAR (EULAR, 2007).
50. European League Against Rheumatism (EULAR). EULAR mission statement. EULAR https://www.eular. org/eular-mission.cfm (2005).